Replies to post #338590 on Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

High efficacy rates across all brilacidin treatment groups, including both single-dose regimens.
-There were no treatment-related SAEs or hypertension-related SAEs.
-PK/PD model correctly predicted high efficacy using single doses

Now we need to see good things in our covid trial.

[Jhawker]

Hypertension happens with a number of drugs including Daptomycin the current soc. forABSSSI. In addition it was not considered a serious side effect of B and it is treated easily. All drugs have side effects.! If you can tell us the dose they are using for the covid trial then let us know otherwise you are just guessing.

[roiresearch]

Appreciate the quick tutorial. I guess we'll find out in P2. Most likely will come up at the interim results if it's an issue or not

[cowtown jay]

There is some evidence that Covid causes arterial damage, at least affecting the brain.

"Wednesday, December 30, 2020

NIH study uncovers blood vessel damage and inflammation in COVID-19 patients’ brains but no infection

Results from a study of 19 deceased patients suggests brain damage is a byproduct of a patient’s illness."

https://www.nih.gov/news-events/news-releases/nih-study-uncovers-blood-vessel-damage-inflammation-covid-19-patients-brains-no-infection

I would assume that other organs, such as the lungs, could be similarly affected, but I don't have any information to substantiate that. However, patients with hypertension may already have constricted pulmonary arteries, and a further deterioration of those arteries from Covid infection only makes the onset of ARDS the more likely.

So to me, it makes sense to exclude patients with hypertension from the trial population.

From the power point presentation you linked, I didn't see that a co-therapy was used with brilacidin. But am I correct in thinking that the company is now using remdesivir as a co-therapy? It appears one is needed to assist brilacidin in attacking both infection and inflammation.